AYLA

Ayala Pharmaceuticals Inc
0.503601
0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
0.503601
Volume 0
Bid Price 0.56
Ask Price 0.4784
News -
Day High

Low
0.3568

52 Week Range

High
6.26

Day Low
Company Name Stock Ticker Symbol Market Type
Ayala Pharmaceuticals Inc AYLA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 0.503601 19:00:00
Open Price Low Price High Price Close Price Prev Close
0.503601 0.503601
Trades Volume Avg Volume 52 Week Range
0 0 - 0.3568 - 6.26
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.503601 USD

Period:

Draw Mode:

Ayala Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 7.46M 14.82M 5.97M $ 3.51M $ - -2.83 -0.20
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - 2.70%

more financials information »

Ayala Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical AYLA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.0%
1 Month0.390.5906150.35680.478414976,0850.113629.13%
3 Months0.71160.71160.35680.526721657,520-0.208-29.23%
6 Months1.682.130.35681.30245,520-1.18-70.02%
1 Year5.486.260.35681.63696,193-4.98-90.81%
3 Years15.6628.680.35682.37265,986-15.16-96.78%
5 Years15.6628.680.35682.37265,986-15.16-96.78%

Ayala Pharmaceuticals Description

Ayala Pharmaceuticals Inc clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The company's current portfolio of product candidates, AL101 and AL102, targets the aberrant activation of the Notch pathway with gamma-secretase inhibitors. Its product candidate, AL101, is being developed as a potent, selective, injectable small molecule gamma-secretase inhibitor, or GSI. It is also developing AL101 for the treatment of T-ALL, an aggressive, rare form of T-cell-specific leukemia.